Cooper Companies, Inc. (The) (NYSE:COO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday. The firm currently has a $270.00 price target on the medical device company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 10.29% from the stock’s previous close.

According to Zacks, “The Cooper Companies ended third-quarter fiscal 2017 on a solid note, beating the Zacks Consensus Estimate on both lines. The company has always seen impressive results at its CooperVision business segment. Notably, the segment banks on the platforms of MyDay, Clariti and Biofinity silicone hydrogel lenses. The CooperSurgical segment also delivered strong sales in the quarter. The company provided strong guidance for fiscal 2017. However, the dampening outlook for the CooperSurgical segment indicates looming concerns. Furthermore, intensifying competition in the contact lens space will continue to increase pricing pressure. Cooper Companies has completed the acquisition of Procornea in the recent past. This added a leading ortho-k technology to Cooper Company’s lens portfolio and marked its foray in the emerging myopia controlled markets. The company had an impressive run on the bourse over the last six months.”

Several other brokerages also recently commented on COO. Robert W. Baird restated a “buy” rating and issued a $251.00 price target on shares of Cooper Companies, Inc. (The) in a research report on Thursday, August 24th. J P Morgan Chase & Co restated a “neutral” rating and issued a $206.00 price target (up previously from $200.00) on shares of Cooper Companies, Inc. (The) in a research report on Monday, June 5th. Jefferies Group LLC set a $250.00 price target on shares of Cooper Companies, Inc. (The) and gave the company a “buy” rating in a research report on Thursday, August 17th. Cleveland Research restated a “buy” rating on shares of Cooper Companies, Inc. (The) in a research report on Tuesday, August 22nd. Finally, BMO Capital Markets restated a “buy” rating and issued a $255.00 price target on shares of Cooper Companies, Inc. (The) in a research report on Thursday, July 13th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $246.89.

Shares of Cooper Companies, Inc. (COO) traded up 0.75% on Friday, reaching $246.65. The company’s stock had a trading volume of 15,398 shares. Cooper Companies, Inc. has a 1-year low of $158.73 and a 1-year high of $256.39. The stock has a 50-day moving average of $245.34 and a 200 day moving average of $222.55. The stock has a market capitalization of $12.05 billion, a PE ratio of 36.98 and a beta of 0.59.

Cooper Companies, Inc. (The) (NYSE:COO) last issued its quarterly earnings results on Thursday, August 31st. The medical device company reported $2.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.06. The business had revenue of $556 million during the quarter, compared to the consensus estimate of $552.32 million. Cooper Companies, Inc. (The) had a net margin of 16.45% and a return on equity of 16.00%. The firm’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.30 EPS. On average, equities analysts forecast that Cooper Companies, Inc. will post $9.71 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/08/cooper-companies-inc-the-coo-lifted-to-buy-at-zacks-investment-research.html.

In other Cooper Companies, Inc. (The) news, VP Randal Golden sold 1,621 shares of the stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $243.65, for a total value of $394,956.65. Following the completion of the sale, the vice president now owns 1,731 shares in the company, valued at approximately $421,758.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Paul L. Remmell sold 9,294 shares of the stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $248.46, for a total transaction of $2,309,187.24. Following the completion of the sale, the chief executive officer now owns 6,186 shares of the company’s stock, valued at approximately $1,536,973.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,015 shares of company stock valued at $4,193,502. Insiders own 1.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC lifted its position in Cooper Companies, Inc. (The) by 2.1% in the 2nd quarter. Lord Abbett & CO. LLC now owns 405,831 shares of the medical device company’s stock worth $97,164,000 after buying an additional 8,316 shares in the last quarter. Sentry Investment Management LLC lifted its position in Cooper Companies, Inc. (The) by 0.7% in the 2nd quarter. Sentry Investment Management LLC now owns 2,801 shares of the medical device company’s stock worth $671,000 after buying an additional 19 shares in the last quarter. Toronto Dominion Bank lifted its position in Cooper Companies, Inc. (The) by 25.3% in the 2nd quarter. Toronto Dominion Bank now owns 16,552 shares of the medical device company’s stock worth $3,963,000 after buying an additional 3,344 shares in the last quarter. Advisory Services Network LLC lifted its position in Cooper Companies, Inc. (The) by 30.6% in the 2nd quarter. Advisory Services Network LLC now owns 457 shares of the medical device company’s stock worth $109,000 after buying an additional 107 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Cooper Companies, Inc. (The) in the 2nd quarter worth approximately $423,000. Institutional investors own 96.10% of the company’s stock.

Cooper Companies, Inc. (The) Company Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Get a free copy of the Zacks research report on Cooper Companies, Inc. (The) (COO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.